

Special Issue

PET/CT in Cancers Outcomes Prediction

Message from the Guest Editor

With more recent advances in PET imaging including multiple new, target-specific radiotracers and improved resolution of the PET/CT machines, PET has become an indispensable tool in oncologic management as recommended by the NCCN guidelines for various tumors. There remain many areas of active investigation in using PET in tailoring oncologic management, especially in the case of novel therapies such as immunotherapy and PSMA-based radioligand therapy. At a molecular level, there is a need to better understand the mechanisms underlying the uptake of radiotracers to apply them to the clinical implications. This Special Issue focuses on applications of PET/CT imaging in the prediction of outcome in cancers and aims to cover new advances in PET imaging, including radiomics, theragnostic radionuclide pairs, and machine learning, which have opened new horizons in the application of quantitative and automated analysis of PET/CTs in oncologic imaging and management. Applications of PET in novel therapies such as CAR T-cell therapy and in cases of rare tumors are also of special interest.

Guest Editor

Dr. Ahmad Sharifabrizi

Division of Nuclear Medicine, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA

Deadline for manuscript submissions

closed (28 February 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/179214

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)